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Abstract
There are numerous circumstances where chronic disease is associated with other disorders, especially in diseases like
diabetes with noncommunicable disease risk factors, such as hypertension. This study shows a novel and innovative
combinational proniosomal delivery of combination to beat the reactions by complex therapeutic regimen, and to
improve patient compliance after controlling combinational transdermal delivery of Glibenclamide (GLB) and Atenolol
(ATN) which have not been tried actually. To achieve the above reason, proniosomes were prepared and optimized
utilizing Box-Behnken design. The ideal formulation was chosen by a point prediction method and formulation showed
vesicle size of 562 ± 1.223 nm, entrapment efﬁciency of GLB & ATN 97.037 ± 1.43% and 96.230 ± 1.62% respectively
which were found in concurrence with the predicted value. The optimized combinational proniosomal gel (OCPG)
formulation was additionally assessed for in vitro drug release, In vitro drug permeation, and in vivo pharmacokinetic
study. The OCPG formulation shows the greatest ﬂux over the rabbit skin (128.609 ± 2.24 mg/cm2/h and 322.054 ± 1.53 mg/
cm2/h) of GLB and ATN respectively. The results indicated desired release and permeation proﬁles. OCPG showed
signiﬁcantly (p < 0.001) pharmacokinetic contemplate exhibited that transdermal proniosomal formulation demonstrated improvement in bioavailability of two drugs 129.30 and 174.62 times respectively as that of the oral formulation.
Overall the results show that controlled release GLB and ATN provesicles offer a useful and promising transdermal
delivery system for the treatment of type II diabetes and hypertension by using design. Henceforth this may be an
achievement in treating diabetic hypertensive patient.
Keywords: Atenolol, Glibenclamide, Transdermal delivery, Proniosomes, Combination

1. Introduction

M

edication administration remains the hallmark of drug therapy. A general aspiration
of pharmacotherapy is to ensure a therapeutic
drug concentration in speciﬁc areas of the body
[1]. The Oral administration remains the most
normally used routes for medicine. An oral
medication generally becomes active when it

passes from the gastrointestinal tract and the liver
into the blood, which reduces the bioavailability
and other side effects. But for this combination
medication, it may not be suitable because of the
fact that the time of administration of the two
medications is different, which assumes a vital
role in ingestion of medications in GIT [2]. These
side effects were overcome by one of the alternative routes transdermal drug delivery system
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(TDDS), which is a promising way of drug delivery to maintain a uniform plasma concentration, reduce dosing frequency associated with
improved the patient compliance, and avoid the
gastrointestinal action [3,4]. Transdermal Drug
Delivery Systems (TDDS) rise the alternative
choice for the administration of medications
which permits self-administration and furthermore whenever required to terminate the medication exposure at any point of time [5,6].
Owing to this it exhibits a high level of patient
compliance with low levels of subject variability [7].
Due to the realization of the factors like poor drug
absorption due to permeability barrier (skin), TDDS
is continuously looking into newer lane [8e11]. To
overcome the skin barrier to a certain extent sophisticated technique [12,13] such as with self-regulating
colloidal carriers [14,15]. Vesicular frameworks like
niosomes show proof of noteworthy potential for
success over such boundary. They collaborate with
the stratum corneum layer to improve the permeation
of drug and furthermore, it goes about as medication
for controlling the release [16,17].
Diabetes mellitus (Type 2 diabetes) is associated
with an increased risk of death due to cardiovascular
disease (CVD) where hypertension is a major risk
factor. Present medication systems for the treatment
of such chronic coexisted diseases are inconvenient
to overcome the side effects. Therefore, investigations are desired to deliver antidiabetics and
antihypertensives using new delivery approaches.
Around 285 million (6%) individuals worldwide is
assessed to have diabetes and 972 million (26%) have
hypertension. 40e80% of diabetes individuals likely
to have hypertension [18e20].
Patients with these comorbid conditions about to
take more medications per day. Instead of taking 2
or more medications they can take a single medication with this combination thereby they follow a
full treatment regimen and furthermore to decrease
high day by day costs [21]. Instead, Transdermal
administration would provide a continuous stimulation of insulin production and reduce the blood
pressure levels simultaneously and thereby help to
reduce these complications. This has been proved
for the administration of Antihypertensives with a
rapid onset of action on awakening in the early
morning seems to be a more rational and beneﬁcial
alternative than the conventional administration
after breakfast [22].
Glibenclamide (GLB) is a prevalent medication and
is generally utilized for treating type II diabetes [23].
Gastric aggravations like queasiness, vomiting,

heartburn, anorexia and increased hunger after oral
treatment is the most well-known symptoms where it
is directed for a long time. Atenolol (ATN), a bblocker, is recommended broadly in various cardiovascular maladies. Organization of traditional tablets
of ATN has been accounted for to display changes in
the plasma sedate dimensions, bringing about either
indication of reactions or decrease in medication
focus at the receptor site [24]. From the literature, it is
evident that b - blockers lessen irregular cardiovascular events when used in assistant evasion after
Myocardial Infarction for both diabetic and nondiabetic patients. Evidence that diabetic patient may
experience more prominent cardio protection with bblockade than do nondiabetic patients [25].
This investigation exhibits a new combinational
proniosomal transdermal delivery of ATN and GLB
to conquer the symptoms by complex therapeutic
regimen and to improve patient compliance after
administering combinational transdermal delivery of
GLB and ATN which have not been formulated so far.

2. Materials and methods
ATN and GLB is a gift sample obtained from Sun
Pharma Ltd, Mumbai, India. Span 60 and cholesterol were purchased from SD Fine Chemicals
(Mumbai, India). Phospholipid 90G is a gift sample
obtained from Lipoid, Nattermannallee 1, D50829 K€
oln and Germany. Potassium dihydrogen
orthophosphate, Acetonitrile, Ethanol-AR, Cholesterol, Sodium hydroxide, Orthophosphoric acid,
Carbopol® and Potassium dihydrogen orthophosphate were purchased from E Merck (Mumbai,
India). All the reagents used are of analytical grade.
2.1. Analysis of GLB and ATN
The concentration of the combination of GLB and
ATN in the samples was analyzed by using HPLC
method (Water 2690 composed of PDA-2996 detector) with BDS C18 250  2.1 mm, 1.6 m columns. Data
acquisition, recording, and chromatographic integration were performed by Empower 2 software.
The mobile phase consisting of 0.01N potassium
dihydrogen orthophosphate (pH 4.8) and acetonitrile (ACN) taken in the ratio 55:45 with an injection
volume 1.0 ml in gradient mode with column oven
temperature maintained at 30  C and elution
monitored by a detector wavelength at 235.0 nm.
2.2. Differential scanning calorimetry (DSC)
DSC was performed using a DSC instrument
(Horiba, Germany). About 5 mg of ATN, GLB, and
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Optimized combination proniosomal gel (OCPG)
were individually capped in the aluminum crucible.
The crucible was kept under a dynamic atmosphere
of nitrogen (50 ml/min) and a heat ﬂow rate of
10  C/min from 30 to 200  C and the corresponding
spectra between heat ﬂow (w/g) on Y-axis and
temperature on X-axis were obtained.
2.3. Fourier transform infrared (FTIR) spectroscopy
Infrared spectroscopy of ATN, GLB, span 60,
Phospholipid 90G, Cholesterol and OCPG individually were analyzed by ALPHA-T (Brucker) FTIR
Spectrophotometer and the spectra were recorded
in the region of 4000e400 cm1.

compositions of different proniosomal formulations
are listed in Table 2. Using a wide-mouth glass tube,
pr
ecised amounts of drugs with surfactant, Phospholipid 90G, and cholesterol was mixed with 2.5 ml
of absolute ethanol. The open end of the glass tube
was covered with a lid to prevent loss of solvent,
after mixing all ingredients and then warmed in a
water bath at 60e70  C for about 5min, until the
surfactants were dissolved completely. The aqueous
phase (pH 7.4 phosphate buffer) was then added
and warmed in a water bath till clear solution was
formed. The mixture was allowed to cool to room
temperature until the dispersion was converted to
proniosomal gel. Proniosomal gel was then mixed
with 1% Carbopol® gel in 1:1 ratio. The gel obtained
was preserved in dark until characterization.

2.4. Preparation of proniosomes
2.5. Box Behnken experimental design
Proniosomes were prepared by the method reported by Perrett et al. [26] and Vora et al., [27]. The
Table 1. Independent and dependent variables used in BoxeBehnken
design for the development and optimization of proniosomal
combination.
Variables

Levels

Independent Variables
X1 ¼ Span 60 (mg)
X2 ¼ Cholesterol (mg)
X3 ¼ Phospholipid (mg)

1
450.00
150.00
900.00

þ1
900.00
250.00
1200.00

0
675
200
1050

Dependent Variables

Constraints

Vesicle Size (Y1)
EE% of GLB (Y2)
EE% of ATN (Y3)

Minimum
Maximum
Maximum

To assess the interaction impacts of surfactant,
lipid, and Cholesterol in the formulations; 3-factor,
3-level Box Behnken conﬁguration was utilized. An
absolute 17 test runs were produced by design
expert Version 11 software. The independent variables were surfactant (Span 60) (X1), Cholesterol (X2)
and lipid (Phospholipid 90G) (X3) while Vesicle size
(VZ) (Y1) entrapment efﬁciency of GLB (Y2) and
entrapment efﬁciency of ATN (Y3) were the dependent variables. The scope of independent variables
was selected based on the results of different initial
trials and literature. The dependent and independent variables were tabulated in Table 1. Further, the
optimum formulation was chosen by the numerical

Table 2. Observed response in BoxeBehnken design for development and optimization of proniosomal combination generated by Design Expert
Software.
Run

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

Factor 1

Factor 2

Factor 3

Response 1

Response 2

Response 3

A: Surfactant

B: Cholesterol

C: Phospholipid

Vesicle Size

Entrapment
Efﬁciency of GLB

Entrapment
Efﬁciency of ATN

mg

mg

mg

nm

%

%

1
0
0
1
0
þ1
0
0
þ1
0
0
þ1
þ1
1
1
0
0

0
0
1
1
0
0
0
þ1
þ1
0
1
1
0
þ1
0
þ1
0

þ1
0
1
0
0
1
0
1
0
0
þ1
0
þ1
0
1
þ1
0

487
555
564
424
564
524
560
612
534
554
543
454
544
478
520
610
556

±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±

3.12
2.98
1.34
3.21
1.54
2.43
1.65
2.76
3.26
2.34
1.87
1.32
1.75
2.34
3.65
2.87
2.43

91.63
95.98
87.54
83.24
93.26
98.26
95.32
78.65
80.43
95.34
88.35
90.54
96.32
81.54
92.45
78.43
95.65

±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±

0.56
0.21
0.43
1.21
0.22
0.32
0.25
0.54
0.32
0.65
0.78
0.54
0.45
0.65
0.76
0.43
0.98

90.32
94.56
86.43
82.32
92.23
96.96
94.64
79.54
80.35
94.92
87.47
90.34
95.99
80.25
91.43
78.98
96.87

±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±

0.43
0.32
0.64
0.76
0.43
0.21
0.32
0.54
0.65
0.43
0.98
0.76
0.64
0.43
0.65
0.21
0.98
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point prediction methodology utilizing the desirability function. At last, linear regression with
ANOVA was utilized to pick the best-ﬁtted model
and p values below 0.05 were considered as statistically signiﬁcant.
2.6. Characterization of the prepared proniosomes
2.6.1. Vesicle size and size distribution analysis
For all the batches of proniosomes vesicle size
analysis was carried out using Malvern Zetasizer
Nano ZS (Malvern Instruments, UK). The freshly
prepared hydrated niosomes were dispersed in
double distilled water (DDW) and was used to
characterize the vesicle size [28,29].
2.6.2. Encapsulation efﬁciency
A precisely weighed measure of a proniosomal gel
was included 10 ml of pH 7.4 phosphate buffer in a
glass vial and was sonicated in a sonicator. The
medications containing niosomes were isolated
from the untrapped drug by centrifugation at
25,000 rpm at 20  C for 30 min. The supernatant was
recuperated and measured by a UV method for the
two drug content. The percentage of drug encapsulation (EE (%)) was calculated by the accompanying equation:
EE % ¼ [(Ct-Cr)/Ct] Х 100%
where Ct is the concentration of total drug and Cr is
the concentration of free drug [30,31].
2.6.3. Morphology
The shape, surface and size qualities of the prepared proniosomes were seen by scanning electron
microscopy. A dainty layer of formed proniosomes
was spread on a glass slide and watched the structure of the vesicle. Photomicrographs were taken
utilizing Fujiﬁlm Finepix F 40 fd 8.3 MP computerized camera with 3 optical zoom [32,33].
2.6.4. Zeta potential measurement
Zeta potential estimation was done by Malvern
Zetasizer Nano Z (Malvern instrument, Malvern,
Worcestershire, UK) device at 25  C. The zeta potential was determined by applying an electric ﬁeld
to the particles of the colloidal scattering of particles
which then move with a speed related to their zeta
potential [34,35].
2.6.5. In vitro drug permeation studies
In-vitro drug permeation studies of the optimized
proniosomal formulation were performed by Franz
diffusion cells with a diffusional area of 3.14 cm2. An

egg layer [36] was set among donor and receptor
compartments. The OCPG was spread on egg ﬁlm.
The receptor compartment contained phosphate
buffer pH 7.4 and was constantly mixed by remotely
determined Teﬂon-coated magnetic bead. The
temperature of the cell was kept up at 37 ± 1  C, to
mimic the physiological conditions. Aliquots (1 ml
each) were gathered at regular time interval for 24 h
and measured for the two drugs concentration utilizing HPLC technique as depicted previously. Each
release study was performed in triplicate [37].
2.6.5.1. Method for egg membrane preparation. The
contents of eggshells were removed and then it was
dipped in the dilute hydrochloric acid for 30 min.
The egg membrane was separated manually and
washed thoroughly with distilled water [36].
2.6.5.2. Kinetic analysis of drug-release proﬁles. To
consider the drug-release mechanism from proniosomes, the release data were ﬁtted to the zero-order
kinetics as cumulative percent of drug released
versus time, the Higuchi model as cumulative percent
drug released versus square root of time and the
Korsmeyer Peppa's kinetics models as log cumulative
percent drug released versus log of time [38].
2.7. Ex vivo permeation study
2.7.1. Preparation of rabbit skin
The preparation of skin was as per Xi et al. [39].
Rabbits weighing 2.0e2.5 kg were bought from the
National center for laboratory animal sciences
(NCLAS). This study convention was endorsed by
the Animal Ethics Committee IAEC (1220/PO/Re/S/
08/CPCSEA). After the rabbit was anesthetized with
urethane (20%, w/v), the hair of abdominal area was
carefully removed. The side of stratum corneum
was extracted after the rabbit was yielded and the
sub-dermal tissue was painstakingly expelled. The
side of stratum corneum was cleaned delicately with
reﬁned water. The skin was washed with PBS,
wrapped in aluminum foil and stored in a deep
freezer at 20  C till further use (used within 2
weeks of preparation) [40].
2.7.2. Skin permeation studies
A two-chamber horizontal Franz diffusion cell
(volume of 15 ml and surface area of 3.14 cm2) was
utilized and the system was kept up at 37 ± 0.5  C
with water bath. OCPG was spread on the stratum
corneum side and two dissemination cells were
clipped together. The receptor chamber was loaded
up with phosphate buffer saline (pH 7.4), which was
consistently mixed at 600 rpm. A sample of 2.0 ml
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was withdrawn at the time points of 2, 4, 6, 8, 10, 12,
24 h and replaced with fresh receptor ﬂuid quickly
to keep up a constant volume. The sample was
examined utilizing the HPLC for drug release [41].
Steady state ﬂux (J ss) ¼ Q/(t  A)
where,
Q ¼ amount of drug permeated
t ¼ time
A ¼ area of membrane
2.8. In-vivo absorption studies
The in-vivo study protocol was afﬁrmed by the
Animal Ethics Committee IAEC (1220/PO/Re/S/08/
CPCSEA). The rabbits (n ¼ 3) were housed in an
animal, place of the Institute. The entire animals
used in the examination were conﬁned and kept up
according to the principles of CPCSEA and standards developed for care and use of research center
animals [42]. Rabbits fasted for 18 h; but, water was
given all through the examination. Rabbits were
partitioned into 3 groups (n ¼ 3). Group I: Control
(pure drugs) given orally, Group II: treated with
marketed preparations orally, Group III: Proniosomal gels (OCPG) applied as a gel to the skin (70).
The portion was offered proportionately to body
weight. Blood samples (0.7 ml) were collected from
the marginal ear vein in the heparinized tube at the
explicit time interims of 0, 1, 4, 8, 12, 16 and 24 h [43].
2.9. Pharmacokinetic analysis
The pharmacokinetic analysis of the GLB and
ATN plasma concentrationetime proﬁle was
assessed using Thermo Kinetica (ver. 5.0; Thermo
Fischer scientiﬁc). Different pharmacokinetic parameters such as Cmax (the maximum plasma concentration) and Tmax (time to reach maximum
plasma concentration) were directly obtained from
the plasma concentration versus time curve [44].
The area under the curve from 0 to t (AUC 0-t), 0 to
∞ (AUC 0-∞) were computed by trapezoid rule and
elimination half-life (t1/2) was calculated by using
the formula t1/2 ¼ log 2/Kel and elimination rate
constant (Kel) was calculated from the slope of log
plasma concentration versus time plot. The relative
bioavailability of the drug after the test formulation
transdermal Vs the oral application was calculated
by using formula F % ¼ AUC test/AUC Control*100.
2.10. Stability studies
The OCPG formulation was subjected to stability
studies to evaluate any physical or chemical changes
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in storage. Gel formulation was kept at 25 ± 2  C/
60 ± 5% RH and 40 ± 2  C/75 ± 5% RH for 3 months
in aluminum foil-sealed glass vials throughout the
study ICH Q1A (R2), [45,46]. The samples were
analyzed for various parameters at 0, 1, 2 and 3
months after storage like Vesicle size, shape, Clarity
and drug content.

3. Results and discussion
In the present investigation, the proniosomes of a
combination of drugs were formulated, optimized
and evaluated for its capability in transdermal delivery to overcome the major issues related to its
oral delivery. The proniosomal gels were studied
using particular non-toxic and biocompatible, nonionic surfactants like spans with cholesterol and
Phospholipid [47]. The proniosomes were set up by
the coacervation phase separation method as stated
by Vora et al. [27].
3.1. Analysis of GLB and ATN
Chromatogram A represents the blank mobile
phase and chromatogram B represents with an
average retention time of 2.322 min for GLB and
3.260 min for ATN and with no interfering peaks
Fig. 1.
3.2. Differential scanning calorimetry (DSC)
DSC thermograms showed the characteristics
endothermic peak for ATN and GLB at 146.39  C
and 173.79  C, corresponding to their melting point.
The result of DSC thermograms of pure drug,
physical mixture and optimized s polymers showed
an endothermic peak at 147  C and 170.07  C. In
addition to this, additional declines in sharpness of
endothermic peak in loaded with drug proniosomal
formulation were notiﬁed. The drug-loaded proniosomes (OCPG) showed the peak at the same
melting point which conﬁrmed the absence of any
chemical interactions between the Drug and proniosomal components as shown in Fig. 2 [48].
3.3. Infrared spectroscopy (FTIR)
The FTIR spectra of Combination of drugs span
60, Phospholipid, Cholesterol, blank and OCPG are
shown in the spectra. FTIR spectra of pure Drugs
showed the characteristic peak at 1515.29 cm1 and
1521.99 cm1 (N]N stretching), 1242.08 cm1 and
1246.56 cm1 (C]C stretching), 2924.46 cm1 and
2931.19 cm1 (CH3 stretching), 1415.09 cm1 and
1455.35 cm1 (CH3 deformation), 3356.86 cm1 and
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Fig. 1. HPLC chromatograms of blank mobile phase spike (chromatogram A) and HPLC chromatograms of mobile phase containing 10 mg/mL GLB &
25 mg/mL ATN (chromatogram B).

3367.54 cm1 (OeH Stretching) for ATN and GLB
respectively. Span 60 showed the characteristic
peaks at 1220 cm1 (aliphatic), 1755 cm1 (cyclic 5membered ring), 1400 cm1 (-CH3), 2928 cm1
(aliphatic CeH stretching, asymmetric and

3400 cm1 (OeH stretching). When the physical
mixture of drugs, span 60, Cholesterol and Phospholipid were analyzed, the characteristics peaks of
drugs were present in physical mixture similar to
that of individual drugs spectrum and there were no

Fig. 2. DSC graphs for pure A) ATN, B) GLB, C) Cholesterol, D) Phospholipid 90G and E) OCPG.
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Fig. 3. FTIR graphs for pure ATN, GLB, Span60, Cholesterol, Phospholipid 90G and OCPG.

detectable changes in FTIR spectra which conﬁrmed
the absence of any chemical interactions between
them as shown in Fig. 3 [49,50].
3.4. Preliminary study
The preliminary study was conducted to evaluate
the effect of various formulation factors such as
vesicle size and entrapment efﬁciency on the release
of both drugs from the gel as well as their permeation proﬁle across an egg membrane. This study
was conducted to evaluate one formulation variable
at a time [29].

efﬁciency of ATN (Y3) were the chosen dependent
responses. Table 2 shows the results of the prepared
15 formulations. Fig. 4 shows the three-dimensional
plots for all the three responses for responses Y1, Y2,
and Y3, respectively. These plots are known to study
the interaction effects of the factors on the responses
as well as being useful in studying the effects of two
factors on the response at one time. Fig. 5 quantitatively compared the resultant experimental values of
the responses with that of the predicted values. The
regression analysis outcome of different responses is
given in Table 3. The Quadratic nature relationships
was afﬁrmed by the larger values of the standard
error for the coefﬁcient.

3.5. Box-Behnken design
Box-Behnken design, a 3-factor, 3-level was used
to investigate quadratic response surfaces and constructing second order polynomial models with
Design Expert 11. The Box-Behnken design was
speciﬁcally selected since it requires fewer runs than
a central composite design [51]. A design matrix
comprising of 17 experimental runs generated by the
Design expert software. The independent variables
selected were the Span 60 (X1), Cholesterol (X2) and
Phospholipid (X3), and; while vesicle size (Y1),
entrapment efﬁciency of GLB (Y2), and entrapment

3.5.1. Response 1 (Y1): effect of independent variables
on vesicle size
For effective transdermal drug delivery, one of the
essential criteria is small vesicle size [52]. The size of
the vesicles was found to shift between 424 ± 3.21 to
612 ± 2.76 nm (Table 2). Primarily, Normal vesicle
size increases with increment in the concentration of
Span 60 yet further increase in the concentration of
Span 60 quick decrease in the normal vesicle size.
The incorporation of spans and cholesterol in the
formulation interacts with the bilayer (lecithin present) and resulted in the increased vesicle size. As
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Fig. 4. 3D-response surface plot showing effect of independent variables such as Span 60, Phospholipid and Cholesterol on (A) Vesicles size (B)
Entrapment efﬁciency of GLB and (C) Entrapment efﬁciency of ATN.

the concentration of span 60 increased in the
formulation, the vesicle size also increased from
424 ± 3.21 to 544 ± 1.75 nm, which is in agreement
with the earlier ﬁndings [53]. Also the incorporation
of lipophilic drugs into the hydrophobic domain of
vesicle causes the bilayer molecules to move apart
from each other, leading to an increase in vesicle
size [54].
The vesicle size was also increased, when the
amount of lecithin in the formulation was increased.
In a similar way, when the amount of cholesterol
was increased from 150 to 250 mg, the size of vesicle
also increased. Elevated cholesterol in the formulation is likewise responsible for the enormous size of
vesicles. It was accounted for that cholesterol
increased the width of the lipid bilayer [27]. This

relationship is displayed by the accompanying
equation.
Vesicle Size (Y1): þ557.80 þ 18.38X1 þ 31.13X2 4.50X3 þ 6.50X1 X2 -13.25X1
X3 þ 4.75X2 X3 -74.40X12
-10.90X22þ35.35X32
The Model F-value of 151.25 implies the model is
signiﬁcant. There is only a 0.01% chance that an Fvalue this large could occur due to noise. Values of
“Prob > F00 less than 0.05 indicated that the model
terms are signiﬁcant. In this case, X1, X2, X3, X1X2,
X1X3, X2X3, X12, X22, X32 are signiﬁcant model
terms. There is an 18.66% chance that a Lack of Fit
F-value this large could occur due to noise. The
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Fig. 5. Linear correlation plots (A, C, E) between actual and predicted values and the corresponding residual plots (B, D, F) for various responses.

Predicted R2 of 0.9430 is in reasonable agreement
with the Adjusted R2 of 0.9883; i.e. the difference is
less than 0.2. Adeq Precision measures the signal to
noise ratio. A ratio greater than 4 is desirable. Your

ratio of 44.411 indicates an adequate signal. This
model can be used to navigate the design space.
There existed a direct relationship between the Span
60 concentration and cholesterol on the vesicle size.

Table 3. Summary of results of regression analysis for responses Y1, Y2and Y3 for ﬁtting to quadratic model.
Quadratic model

Lack of Fit p-value

Adjusted R2

Predicted R2

Response (Y1)
0.1866
0.9883
0.9430
Response (Y2)
0.1670
0.9548
0.7742
Response (Y3)
0.4187
0.9406
0.7821
Regression equation of the ﬁtted quadratic model
Vesicle Size (Y1): þ557.80 þ 18.38X1 þ 31.13X2 - 4.50X3 þ 6.50X1 X2 -13.25X1 X3 þ 4.75X2 X3 -74.40X12 -10.90 X22 þ 35.35 X32
EE % of GLB (Y2) ¼ þ95.11 þ 2.09X1-3.83X2-0.2713 X3-2.10 X1X2-0.2800 X1X3-0.2575 X2X3-0.1250 X12-11.30 X22-0.5700 X32
EE % ATN (Y3) ¼ þ 95.86 þ 1.91 X1 - 3.93 X2 -0.2000 X3 -1.48 X1 X2 - 0.4650 X1 X3-0.4000 X2 X3 -0.4855 X12 -11.06 X22 -0.6955 X32
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Linear correlation plots (A) between actual and
predicted values and the corresponding residual
plots (B) for the responses are presented in Fig. 5.
3.5.2. Response 2 (Y2): effect of independent variables
on EE% of GLB
Entrapment efﬁciency (%EE) is the percentage
fraction of the total drug (GLB) entrapped into the
vesicles (Table 2). The encapsulation efﬁciency was
found to be higher in case of proniosomes prepared
with spans with large saturated alkyl chain when
compared to tweens with small saturated alkyl
chain. This could be explained on the basis of their
HLB values. Spans being lipophilic in nature, having low HLB value, formed a well closed uniform
packed bilayer structure within which highly lipophilic GLB gets almost completely packed [55]. It
can be observed clearly that when cholesterol was
used in 150e200 mg concentration, there was a
signiﬁcant increase in entrapment efﬁciency, further
increase in cholesterol concentration leads to a
relative decrease in %EE. Phospholipid also plays a
substantial role in the entrapment efﬁciency of GLB
[43]. In addition, the nature of the drug also plays a
signiﬁcant role in the entrapment efﬁciency of drug
because the drug is entrapped in the lipid phase.
GLB is a lipophilic drug, so that the entrapment
efﬁciency noticeably was found to be higher [48].
EE % of GLB (Y2) ¼ þ95.11 þ 2.09X1-3.83X2-0.2713
X3-2.10 X1X2-0.2800 X1X30.2575 X2X3-0.1250 X12-11.30
X22-0.5700X32
The Model F-value of 38.58 implies the model is
signiﬁcant. There is only a 0.01% chance that an Fvalue this large could occur due to noise. The Predicted R2 of 0.7742 is in reasonable agreement with
the Adjusted R2 of 0.9548; i.e. the difference is less
than 0.2. Adeq Precision measures the signal to
noise ratio. A ratio greater than 4 is desirable. Your
ratio of 16.731 indicates an adequate signal. This
model can be used to navigate the design space. The
average Entrapment Efﬁciency of GLB was 88.79%
with a minimum of 78.43% and a maximum of
98.26%. Linear correlation plots (C) between actual
and predicted values and the corresponding residual plots (D) for the responses are presented in
Fig. 5. According to Mokhtar et al. [56] the entrapment of drug happened in both bilayer and watery
compartment of the vesicles. At the point when the
lipid compartment and the aqueous compartment
saturated with the drug, the vesicles gave constrained entrapment capacity, which is also
mentioned by Lopes et al., [57].

3.5.3. Response 3 (Y3): effect of independent variables
on EE% of ATN
Entrapment efﬁciency (%EE) is the percentage
fraction of the total drug (ATN) entrapped into the
vesicles (Table 2). It is observed from the experimental design that entrapment efﬁciency has a
direct positive relationship with the concentration of
Span 60, Cholesterol and Phospholipid also play a
substantial role in the entrapment efﬁciency of ATN
[43] as revealed by the following equation. In addition, the nature of the drug also plays a signiﬁcant
role in the entrapment efﬁciency of drug because
the drug is entrapped in the lipid phase. Spans
being lipophilic in nature, having low HLB value,
they don't form a well closed uniform packed
bilayer structure within which highly hydrophilic
ATN, which exhibit a leakier and permeable bilayer
structure resulted in low entrapment efﬁciency
when compared to GLB [48].
EE % ATN (Y3) ¼ þ 95.86 þ 1.91 X1 - 3.93 X2 -0.2000
X3 -1.48 X1 X2 - 0.4650 X1 X30.4000 X2 X3 -0.4855 X12 -11.06 X22
-0.6955 X32
The Model F-value of 29.14 implies the model is
signiﬁcant. There is only a 0.01% chance that an Fvalue this large could occur due to noise. The Predicted R2 of 0.7821 is in reasonable agreement with
the Adjusted R2 of 0.9406; i.e. the difference is less
than 0.2. Adeq Precision measures the signal to
noise ratio. A ratio greater than 4 is desirable. Your
ratio of 14.206 indicates an adequate signal. This
model can be used to navigate the design space. The
average Entrapment Efﬁciency A was 83.86% with a
minimum of 78.98% and a maximum of 96.96%.
Linear correlation plots (E) between actual and
predicted values and the corresponding residual
plots (F) for the responses are presented in Fig. 5.
3.5.4. Numerical point prediction method
The optimum formulation of Proniosomal system
was selected based on the criteria of attaining the
reasonable value of vesicles size, entrapment efﬁciency of GLB and entrapment efﬁciency of ATN by
applying numerical point prediction optimization
method of the Design Expert software 11. The
formulation composition with Surfactant (Span 60)
(830.272 mg), Cholesterol (191.219 mg) and Phospholipid (900.00 mg) with desirability of 0.966 were
found to fulﬁll the requisites of an optimized combination proniosomal Gel (OCPG) formulation. The
morphology of the optimized formulation was
observed by scanning electron microscopy. The
picture demonstrated that the drug entangled in the
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observed clear, free from particles and demonstrated great homogeneity with nonappearance of
irregularities.
3.6.1. Vesicle size and particle size distribution
The results showed that OCPG dispersion effectively decreased the particle size with narrow size
distribution. The average particle size of the OCPG
was found to be 564 ± 2.13 nm. Vesicles size distribution of optimized formulation is presented in
Fig. 7.
Fig. 6. SEM image of OCPG.

lipid network. They show well recognized round
vesicles with uniform size, showing ﬁxed nano-vesicular structure (Fig. 6). The OCPG formulation
gives the experimentally observed values of vesicle
size of 562 ± 2.13 nm with the entrapment efﬁciency
of GLB is 97.037 ± 1.43% and entrapment efﬁciency
of ATN is 96.230 ± 1.62%. These investigative estimations of vesicles size, entrapment efﬁciency of
GLB and entrapment efﬁciency of ATN yielded by
the OCPG were found in agreement with the predicted value of vesicles size (562 ± 1.223 nm),
entrapment efﬁciency of GLB (97.13 ± 1.47%) and
entrapment efﬁciency of ATN (97.42 ± 1.85%)
respectively created by design expert software, recommending that the optimized formulation was
rational and reliable.
3.6. Evaluation of OCPG
The OCPG formulation was the smooth surface
with uniform and consistent appearance. As per
Ganeshpurkar et al. [58] the pH value of OCPG
which was found at 7.2 ± 0.1 and it is viewed as
satisfactory with no danger of aggravation on
application to the skin. Formulated OCPG was

3.6.2. Zeta potential
Zeta potential is the measurement of electric
charge present on the surface of the particles. Zeta
potential of ﬁnally OCPG formulation was found to
be 30.8 ± 1.13 mV (Fig. 7), the value of zeta-potential in a range of higher than ±30 mV electrostatic
charge indicates long term stability.
3.6.3. In vitro drug permeation studies
In drug release kinetics, the model revealing the
highest value of R2 (correlation coefﬁcient) was
inferred an as the best model for drug release kinetics. The drug release from OCPG through rabbit
skin was ﬁtted into different mathematical models
such as zero-order release kinetics, Higuchi's square
root of time equation [59] and Korsmeyer Peppas'power law equation [60,61]. The highest value of the
correlation coefﬁcient (R2 ¼ 0.990 for GLB and 0.996
for ATN) was observed in the Higuchi matrix model,
followed by the zero order (R2 ¼ 0.980 for GLB and
0.985 for ATN) and Korsmeyere Peppas (R2 ¼ 0.945
for GLB and 0.910 for ATN), models. In the greater
part of the transdermal system, drug diffusion from
the dosage form pursues the diffusion pattern
shown in Fig. 8 [62]. Same release kinetics for proniosomes formulation was accounted for by previous researchers [29,52,63,64,65].

Fig. 7. Vesicles size distribution and Zeta potential of OCPG.
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Fig. 8. In vitro and ex vivo drug permeation plot for OCPG.

h) of GLB and ATN respectively. Our ﬁndings were
comparable as given by Imam et al. [53] where
proniosomes containing Span indicated higher ﬂux
than with the other, which could be because of their
less lipophilicity which drove them [67].

Fig. 9. Plasma Concentration-time curve for OCPG.

3.6.4. Skin permeation studies
The release rate of OCPG over the egg layer and
excised skin varies essentially, which demonstrates
about the hindrance properties of skin which was
shown in Fig. 8. The Combination of niosomes to the
skin surface brought about a higher transition
because of the immediate exchange of drug from the
vesicles [66]. It is obvious that OCPG formulation
demonstrated the greatest ﬂux over the rabbit skin
(128.609 ± 2.24 mg/cm2/h and 322.054 ± 1.53 mg/cm2/

3.6.5. In vivo drug absorption studies
The peak area of GLB and ATN in plasma was
linear with respect to the analyte concentration over
the range 14e560 ng/ml and 10.5e420 ng/ml. Validated analytical method was found satisfactory and
proved to be adequate for the determination of both
drugs in plasma. The In vivo drug release studies
were found in Fig. 9. The corresponding pharmacokinetic parameters of rabbit plasma were summarized in Table 4.
3.6.6. Pharmacokinetic analysis
The in-vivo study was performed on rabbits
(n ¼ 3) and the pharmacokinetic parameters for two
API, marketed formulation and transdermal proniosomes (OCPG) were determined and listed in
Table 4. The transdermal proniosomes exhibited the
maximum plasma drug concentration (Cmax) of
141.76 ± 13.15 ng/ml for GLB and 137.64 ± 11.06 ng/

Table 4. Pharmacokinetic parameters of ATN and GLB in rabbits.
S.No

Pharmaco-kinetic
Parameters

Control Formulation

Marketed Formulation

OCPG Formulation

GLB

ATN

GLB

ATN

GLB

ATN

1
2
3
4
5
6
7
8

Tmax (h)
Cmax (ng/ml)
AUC0et (ng h/ml)
AUC0e∞ (ng h/ml)
Kel(h1)
t1/2
MRT
F%

1 ± 0.16
273.45 ± 10.52
1309.46 ± 1.13
1408.25 ± 1.46
0.098 ± 0.03
7.05
8.04977
-

1 ± 0.12
250.54 ± 12.16
1099.34 ± 1.18
1152.59 ± 2.75
0.112 ± 0.0.06
6.18
6.67152
-

4 ± 0.53
241.58 ± 11.52
2126.88 ± 2.41
2397.83 ± 1.74
0.0809 ± 0.02
8.562 ± 0.07
11.347
-

4 ± 0.08
187.62 ± 12.14
1522.6 ± 2.68
1676.28 ± 4.14
0.1049 ± 0.003
6.6025 ± 0.04
10.7506
-

12.00 ± 0.23
141.76 ± 13.15
2750.21 ± 3.15
3382.17 ± 2.42
0.099 ± 0.03
6.94107 ± 0.01
16.056
129.30

12.00 ± 0.06
137.64 ± 11.06
2658.91 ± 1.41
3222.55 ± 1.15
0.104 ± 0.0.03
6.61 ± 0.23
15.695
174.62

23

564 ± 12.98 nm
and Round
560
±15.87 nm
and Round

585 ± 15.87 nm
and Round
582 ± 16.98 nm
and Round

At Room temperature
2.

98.31 ± 0.3

98.12 ± 0.5

560 ± 17.8 nm
and Round
98.43 ± 0.3
98.65 ± 0.3

580
±12.76 nm
and Round
560 ± 15.87 nm
and Round
97.98 ± 0.5
At refrigerator
1.

98.01 ± 0.2

3
2

580 ± 15.4 nm
and Round
98.23 ± 0.2
98.33 ± 0.3

2
0
1
0

1

Vesicle size and Shape
% Drug Content
Temperature
S. No.

Table 5. Stability studies of formulation OCPG.

ml for ATN (p < 0.0001) whereas two API's oral solution of GLB and ATN have Cmax of
273.45 ± 10.52 ng/ml and 250.54 ± 12.16 ng/ml and
the marketed oral solution of GLB and ATN have
Cmax of 241.58 ± 11.52 ng/ml and 187.62 ± 12.14 ng/
ml respectively. The Cmax of OCPG was lower
(141.76 ± 13.15 ng/ml for GLB and 137.64 ± 11.06 ng/
ml for ATN) than the oral formulation signiﬁcantly
lower than oral formulation (241.58 ± 11.52 ng/ml
and 187.62 ± 12.14 ng/ml respectively) which can be
allotted because of the control release in test
formulation as against the variable assimilation
(peak and valley design) which is incommodious
characteristic for oral marketed formulation which
was mentioned in earlier ﬁndings for GLB in
Mohammed Aslam et al. [68] and for ATN in JunShik Choi et al. [69]. The low Cmax and delayed Tmax
seen with the transdermal formulation as opposed
to the oral can be ascribed to the effective boundary
properties of the skin which was seen in past ﬁndings of M. Aqil et al. [70,71]. The area under the
curve (AUC) represents the extent of drug absorption (bioavailability) from its dosage form. It was
observed that Signiﬁcantly high (p < 0.0001)
AUC(0e24) and AUC(0e∞) for proniosomes for GLB
and ATN was 2750.21 ± 3.15 ng h/ml;
3382.17 ± 2.42 ng h/ml and 2658.91 ± 1.41 ng h/ml;
3222.55 ± 1.15 ng h/ml whereas this value for two
API's is 1309.46 ± 1.13 ng h/ml; 1408.25 ± 1.46 ng h/
ml and 1099.34 ± 1.18 ng h/ml; 1152.59 ± 2.75 for
marketed preparation it is 2126.88 ± 2.41 ng h/ml;
2397.83 ± 1.74 ng h/ml and 1522.6 ± 2.68 ng h/ml;
1676.28 ± 4.14 ng h/ml. However, the AUC values
were altogether higher due to the avoidance of hepatic metabolism by transdermal administration
providing high systemic drug availability which is
indicated by increased bioavailability of the drug
from transdermal route as compared to oral
administration. The AUC 0/∞ of transdermal
administration was 1.29-fold higher than that of oral
administration alone. The relative bioavailability of
proniosomes of GLB and ATN was found to be
126.85 and 174.30 times compared to marketed oral
preparation which indicated that OCPG transdermal preparation can also be used as an alternative to oral route.
Time taken to achieve the peak plasma drug
concentration (Tmax) was fundamentally delayed to
12h in both instances of proniosomes which was 1h
and 4 h in case of two API's and marketed preparation, which obviously demonstrated the boundary
properties of the skin. These values were signiﬁcantly higher as compared to control and marketed
oral suspension (p < 0.001). Our results were in
agreement to Sharda Sambhakar et al. [72] who
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moreover reported the expansion in tmax when the
proniosomes were given through transdermal route
in rats. No huge changes in t1/2 were seen with the
proniosomal formulation with that of the API and
marketed formulation [73,74].
3.7. Stability studies
The inﬂuence of elevated temperature and humidity conditions on the proniosomes gel formulation was performed in adherence to the ICH
guidelines. There was no signiﬁcant reduction in the
drug content value of the OCPG formulation before
and after three months of storage (Table 5). The
proniosomal gel was also examined microscopically
which showed round shaped vesicles. There was not
much difference in the clarity which is clear and the
size of the vesicles before and after storage. Therefore, the proniosomal gel formulations can be stored
either at refrigeration or at room temperature
[75,76].

4. Conclusion
This study presents here reports of fruitful design
and evaluation of a combined proniosomal gel for
transdermal delivery for treating concurrent disease
especially diabetes with hypertension. We conveyed
the widely used antidiabetic and antihypertensive
since adherence with these medications is quite
poor, and the utilization of this combination is to
manage long-acting medicine, which releases drugs
at the same time, simpliﬁes complex therapeutic
regimen, and to improve acceptability and adherence. This kind of system may give an alternative
method of conveyance for patients who are taking
multiple medications, following complex treatment
regimens in concurrent diseases like diabetes with
hypertension. If clinical beneﬁts can be shown, then
possibly health care providers would be willing to
pay attention slightly more than they currently do
for single oral medicines in such concurrent diseases. Combinational Proniosomal gel represents a
promising technology that could be used for transdermal delivery of many other established drugs
which are used for treating these types of concurrent diseases.
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